Phase II study of 18F fluorothymidine positron emmission tomography (FLTPET) in the follow up of glioblastoma multiforme patients treated with combined radiotherapy and chemotherapy.
Completed
- Conditions
- Braintumor (GBM)
- Registration Number
- NL-OMON23615
- Lead Sponsor
- MCGroningen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Patients with histologically confirmed newly diagnosed glioblastoma multiforme
(World Health Organization [WHO] grade IV astrocytoma) with indication and
eligibility for radiotherapy and concomitant TMZ followed by adjuvant TMZ. Patients
must have clinically and radiographically documented measurable disease.
Conventional MRI post surgery must be performed within 28 days prior to start of
combined treatment;
Exclusion Criteria
1. Patients with no histologically confirmed newly diagnosed glioblastoma multiforme
(World Health Organization [WHO] grade IV astrocytoma) or without indication and
eligibility for radiotherapy and concomitant TMZ followed by adjuvant TMZ. No conventional MRI post surgery;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method